Eli Lilly | Les Charges D'Exploitation



Operating Expenses Changement Date
AbbVie USD 9.61B 6.98B 2025-03
Abbott USD 8.7B 363M 2025-03
ALKERMES USD 267.3M 6.09M 2024-12
Amgen USD 6.78B 401M 2024-12
AstraZeneca USD 9.91B 2.94B 2025-03
Baxter International USD 3.19B 644M 2024-12
Biogen USD 2.01B 13.3M 2024-12
Bristol-Myers Squibb USD 8.23B 3.32B 2025-03
Drreddys Laboratories INR 64.87B 2.26B 2024-12
Eli Lilly USD 7.32B 1.06B 2025-03
Gilead Sciences USD 4.43B 687M 2025-03
GlaxoSmithKline GBP 5.3B 2.12B 2025-03
Glaxosmithkline GBP 7.42B 408M 2024-12
Indivior 200M 193M 2025-03
J&J USD 8.26B 10.37B 2025-03
Medtronic USD 6.65B 162M 2025-01
Merck USD 9.66B 1.67B 2025-03
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Novartis USD 10.15B 579M 2024-12
Novo Nordisk 37.49B 4.64B 2024-09
Perrigo USD 1.03B 13.4M 2024-12
Pfizer USD 10.05B 8.12B 2025-03
Prestige Brands USD 198.36M 1.09M 2024-12
Regeneron Pharmaceuticals USD 2.44B 362M 2025-03
Roche Holding CHF 11.43B 1.48B 2024-12
Sanofi EUR 8.32B 1.55B 2025-03
Sanofi EUR 6.77B 3.75B 2024-12
United Therapeutics USD 411.6M 33.4M 2025-03
Zoetis USD 1.59B 71M 2024-12



Eli Lilly Les Charges D'Exploitation - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.